Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Phase II, Multicentre; Randomised, Dose-finding, Double-blind and Placebo Controlled Superiority Study With Parallel Groups

Next Previous
X
Search
Trial Profile

Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Phase II, Multicentre; Randomised, Dose-finding, Double-blind and Placebo Controlled Superiority Study With Parallel Groups

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Revacept (Primary)
  • Indications Carotid stenosis; Embolism and thrombosis; Stroke; Transient ischaemic attacks
  • Focus Proof of concept; Therapeutic Use
  • Sponsors advanceCor

    • Most Recent Events

    • 25 Aug 2022 According to an AdvanceCOR media release, Professor Klaus Groschel is the principal investigator for this study.
    • 25 Aug 2022 Results published in the advanceCor Media Release.
    • 13 Jun 2022 Primary endpoint has not been met. (stroke or death, transient ischemic attack, myocardial infarction, coronary intervention, and bleeding complications during follow-up- 40 mg Revacept), as per Results published in the Stroke, as per Results published in the Stroke

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top